Veronique Foutel - DBV Technologies Chief Strategic Marketing Officer

DBV Stock  EUR 1.33  0.02  1.48%   

Executive

Ms. Veronique Foutel has served as Director of Strategic Marketing of DBV Technologies SA since June 6, 2013. She gained experience of almost two decades in drug asset value identification, evaluation, creation, dissemination and confirmation through the tenure of diverse and complementary roles initially held within the French Health Authorities and later on in the Pharma Industry, mainly in the Pharma Division of Roche between 1996 and 2012 in Western Europe, in North America and at its Headquarters in Switzerland. She holds a Doctorate of Phylosophy degree in Pharmaceutical Sciences from Universite Paris V Rene Descartes and is a former hospital resident of Assistance Publique Hopitaux de Paris. since 2013.
Age 45
Tenure 11 years
Phone33 1 55 42 78 78
Webhttps://www.dbv-technologies.com

DBV Technologies Management Efficiency

The company has return on total asset (ROA) of (0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 12.8 M in total debt with debt to equity ratio (D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. DBV Technologies has a current ratio of 3.51, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist DBV Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, DBV Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DBV Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DBV to invest in growth at high rates of return. When we think about DBV Technologies' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

EXECUTIVE Age

Eric HazaVeolia Environnement VE
N/A
Sylvain BoucherVeolia Environnement VE
N/A
Eliane TallecGaztransport Technigaz SAS
N/A
Helman SechevalVeolia Environnement VE
53
Lelia GhiliniGaztransport Technigaz SAS
N/A
Manuele HatonGaztransport Technigaz SAS
N/A
Stephane BedereSidetrade
N/A
Yoel AttiasSidetrade
N/A
David ColsonGaztransport Technigaz SAS
N/A
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. DBV TECHNOLOGIES operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 97 people. DBV Technologies SA (DBV) is traded on Euronext Paris in France and employs 85 people.

Management Performance

DBV Technologies Leadership Team

Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Ehouarn, Industrial Development and Production Director
Claude Thebault, Medical Director
Wence Agbotounou, Chief Clinical Trial Officer
Laurent Martin, Sr. Executive VP of Regulatory and Product Strategy
Viviane Monges, Non-Executive Independent Director
Caroline Daniere, Chief Human Resource Officer
Claire Giraut, Non-Executive Independent Director
Didier Hoch, Director
Adam Slatter, Chief Quality Officer
Daniel Tass, CEO Director
Daniel Soland, Non-Executive Independent Director
Julie ONeill, Non-Executive Director
Hugh Sampson, Chief Scientific Officer
Pascal Wotling, Chief Technical Operations Officer
Charles Ruban, Chief Development Officer
Nathalie Donne, Director of Bus. Devel. and Corporate Communication
Ramzi Benamar, Chief Financial Officer
Lucie Mondoulet, Director of Research
Anne Pollak, Head Relations
Chahra Louafi, Director - Representative of CDC Entreprises (Innobio)
Peter Hutt, Independent Director
Michele Robertson, Chief Legal Officer
Rafaele Tordjman, Director - Representative of Sofinnova Partners
Bertrand Dupont, Co-Founder and Sr. Executive VP of Technology
MarieCatherine Therene, Deputy Chief Executive Officer and Responsible Pharmacist
Joseph Becker, VP Communications
Sbastien Robitaille, Chief Officer
Veronique Foutel, Chief Strategic Marketing Officer
Daniel Tasse, Chief Executive Officer, Director
Rafale Tordjman, Director - Representative of Sofinnova Partners
Joan Schmidt, Executive Vice President General Counsel
George Horner, Director
Michael Goller, Non-Executive Director
Sebastien Robitaille, Chief Financial Officer
Torbjorn Bjerke, Non-Executive Independent Director
Pharis Mohideen, Chief Medical Officer
PierreHenri Benhamou, Chairman of the Board, CEO
Torbjrn Bjerke, Independent Director
Kevin Trapp, Chief Commercial Officer
Mailys Ferrere, Non-Executive Director
Michel Rosen, Non-Executive Independent Chairman of the Board
David Schilansky, COO

DBV Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with DBV Technologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.

Moving together with DBV Stock

  0.71ALALO Acheter LouerPairCorr
  0.67ALENE Enertime SAS Earnings Call TodayPairCorr

Moving against DBV Stock

  0.55VK VallourecPairCorr
The ability to find closely correlated positions to DBV Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DBV Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DBV Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DBV Technologies SA to buy it.
The correlation of DBV Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DBV Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DBV Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DBV Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DBV Technologies SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade DBV Stock refer to our How to Trade DBV Stock guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for DBV Stock analysis

When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Please note, there is a significant difference between DBV Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if DBV Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DBV Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.